- Home
- ABLV vs TLPH Comparison
ABLV vs TLPH Comparison
Compare ABLV & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | TLPH |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | China | United States |
| Employees | 164 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 42.3M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | ABLV | TLPH |
|---|---|---|
| Price | $1.11 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 101.0K | ★ 287.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.38 |
| 52 Week High | $1.77 | $1.57 |
Technical Indicators
Market Signals| Indicator | ABLV | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 71.20 |
| Support Level | $0.89 | $1.01 |
| Resistance Level | $1.19 | $1.29 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 33.33 | 90.11 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.